Robert Johnson
Adolescent Medicine Newark, NJ Medical Doctor
NPI 1134149230 CMS profile 424074
90 Bergen St, Suite 4300, Newark, NJ 07103
General payments
$6,386
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Robert Johnson of Newark, NJ is reported in the CMS Open Payments database as having received $6,386 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $6,386 | 1 |
Beside peers
- Robert Johnson
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Robert Johnson were reported at $0. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.
Show as a table
| Year | Robert Johnson | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $95 | $36–$198 | $163 |
| 2020 | $0 | $50 | $23–$111 | $114 |
| 2021 | $0 | $67 | $27–$179 | $132 |
| 2022 | $6,386 | $79 | $29–$189 | $149 |
| 2023 | $0 | $100 | $39–$194 | $160 |
| 2024 | $0 | $93 | $38–$195 | $164 |
| 2025 | $0 | $100 | $40–$207 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
11
Drug cost
$24,298
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 11 | $24,298 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in New Jersey
Susan Brill-Goldberg
Adolescent Medicine · New Brunswick, NJ
Amita Patel
Adolescent Medicine · Elizabeth, NJ
Richard Reutter
Adolescent Medicine · Long Branch, NJ
John Cavuto
Adolescent Medicine · Westfield, NJ
Malgorzata Kortowska
Adolescent Medicine · Clifton, NJ
Glenn Palsky
Adolescent Medicine · Lawrenceville, NJ
Related records
Adolescent Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.